You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石四藥集團(02005.HK)首季歸母淨利潤勁升56.5%至3.03億港元
格隆匯 04-19 12:08

格隆匯4月19日丨石四藥集團(02005.HK)公佈截至2022年3月31日止3個月未經審核經營業績。

集團截至2022年3月31日止3個月的未經審核營業額較2021年同期增加40.8%至約17.33億港元(2021年同期:約12.31億港元)。集團截至2022年3月31日止3個月的未經審核毛利約10.19億港元(2021年同期:約7.87億港元),較2021年同期增加29.5%。集團截至2022年3月31日止3個月的未經審核毛利率約為58.8%,較2021年同期下降5.2個百分點,主要原因是原料藥所佔集團未經審核營業額的比例有所提升,而原料藥的毛利率低於藥物製劑。

截至2022年3月31日止3個月,集團未經審核公司股東應占溢利較2021年同期增加56.5%至約3.03億港元(2021年同期:約1.94億港元),主要原因是(i)比較2021年同期,原料藥未經審核營業額大幅增加267.1%,當中咖啡因系列產品的未經審核營業額大幅增加超過7倍,對集團未經審核股東應占溢利作出更大貢獻;(ii)比較2021年同期,由原料藥未經審核營業額增加的原因,銷售費用率(即未經審核銷售費用除以未經審核營業額)有所下降及(iii)截至2022年3月31日止3個月,並無因授出購股權產生的費用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account